Advertisement
UK markets close in 5 hours 10 minutes
  • FTSE 100

    8,224.47
    +44.79 (+0.55%)
     
  • FTSE 250

    20,371.20
    +39.40 (+0.19%)
     
  • AIM

    766.30
    +1.83 (+0.24%)
     
  • GBP/EUR

    1.1810
    +0.0005 (+0.05%)
     
  • GBP/USD

    1.2648
    +0.0007 (+0.05%)
     
  • Bitcoin GBP

    48,552.38
    +211.38 (+0.44%)
     
  • CMC Crypto 200

    1,280.93
    -2.90 (-0.23%)
     
  • S&P 500

    5,482.87
    +4.97 (+0.09%)
     
  • DOW

    39,164.06
    +36.26 (+0.09%)
     
  • CRUDE OIL

    82.39
    +0.65 (+0.80%)
     
  • GOLD FUTURES

    2,339.80
    +3.20 (+0.14%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     
  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     
  • DAX

    18,330.81
    +120.26 (+0.66%)
     
  • CAC 40

    7,504.80
    -25.92 (-0.34%)
     

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.